Windward Bio
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $165.0Mattributed |
|---|---|
| Latest round | seed, $165.0M, 2026-04-01attributed |
| Founded | 2025 |
| Headquarters | Lausanne |
| Industry | bio |
| Stage | series-b+ |
| Website | indwardbio.com |
Windward Bio is a Basel clinical-stage biotech developing long-acting antibodies for asthma, COPD, and other type-2 immune diseases. Lead drug WIN378 is a six-month-dosed anti-TSLP antibody in Phase 2/3. The company has raised over $365M across Series A and crossover financings since 2025.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-01 | seed | $165.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $165.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $165.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | indwardbio.com, read 2026-05-07 |
| Description | self-reported | indwardbio.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.